Clinical Trial Update: A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Status update on a Phase 1/2 clinical trial evaluating ARV-766 taken orally in men with metastatic prostate cancer, sponsored by Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ARV-766

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer Metastatic | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING